



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/091,847	03/06/2002	Neal R. Cutler	CUTLER-06830	9631
7590	12/21/2005		EXAMINER	
MEDLEN & CARROLL, LLP Suite 350 101 Howard Street San Francisco, CA 94105			YEBASSA, DESTA LETTA	
			ART UNIT	PAPER NUMBER
			1615	

DATE MAILED: 12/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT PAPER

20051206

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents


1. The replay filed 19/01/2005 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s) : (see below). See 37 CFR 1.111. Since the above -mentioned replay appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

2. Newly submitted claims 18-23 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: The originally presented claims are drawn to a method of treating migraines, comprising :
(a) providing i) a patient having one or more symptoms of a migraine and ii) a formulation comprising dihydroergtamine;
(b) administering said formulation to said patient sublingually under conditions such that one or more symptoms of said migraine are reduced; whereas the amended claims are drawn to a method of treating migraines, comprising : (a) providing i) a patient having one or more symptoms of a migraine and ii) a formulation comprising dihydroergtamine and STEROID; (b) administering said formulation to said patient sublingually under conditions such that one or more symptoms of said migraine are reduced. The originally presented claims require only dihydroerotamine for treatment of migraines and not STEROID and thus, the newly presented claims are drawn to a new invention.

Since applicant has received an action on the merits for the originally presented invention , this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, said claims are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP 821.03. Failure to present claims drawn to the original invention which were examined on their merits before would result in abandonment of the application.

Desta Yebassa, Ph.D.
Patent Examiner
Art Unit 1615

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

A handwritten signature in black ink, appearing to read "T.K. Page".